



COPY OF PAPERS  
ORIGINALLY FILED

16c1 Schussler  
**RECEIVED**

MAR - 4 2002

TECH CENTER 1600/2900

PATENT APPLICATION

ATTORNEY DOCKET  
NO. 72535

1644

#2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Hans KLINGEMANN )

Serial No.: 10/008,955 )

Filed: December 7, 2001 )

Title: NATURAL KILLER CELL LINES  
AND METHODS OF USE )

Group Art  
Unit: )

Examiner: )

**CERTIFICATE OF MAILING**

I hereby certify that this paper is  
being deposited with the United States  
Postal Service as first class mail in an  
envelope addressed to: Commissioner of  
Patents and Trademarks, Washington, D.C.  
20231, on this date.

2/12/02  
Date

  
Registration No. 30,562  
Attorney for Applicant

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, Applicant, his undersigned  
attorney and assignee submit the following information in connection with the  
above-identified application.

The following United States Patents are listed in chronological order:

**UNITED STATES PATENT DOCUMENTS**

<u>Patent No.</u>	<u>Inventors</u>	<u>Issue Date</u>
5,272,082	Santoli et al.	December 21, 1993
5,772,995	Fakhrai et al.	June 30, 1998
5,981,705	Kornbluth	November 9, 1999

**FOREIGN PATENT DOCUMENTS**

<b><u>Document No.</u></b>	<b><u>Country</u></b>	<b><u>Effective Date</u></b>
WO 94/262841	PCT	November 24, 1994

**OTHER REFERENCES**

Gong Jiang-Hong, et al., "Characterization of a Human Cell Line (NK-92) with Phenotypical and Functional Characteristics of Activated Natural Killer Cells", LEUKEMIA, Vol. 8, No. 4 (April), 1994: pp. 652-658.

Klingemann, Hans-Georg, et al., "A cytotoxic ND-cell line (NK-92) for ex vivo purging of leukemia from blood", Biology of Blood and Marrow Transplantation, 2:68-75 (1996).

Wong, E., et al., "Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12, Bone Marrow Transplantation, (1996) 18, pp. 63-71.

Long, G. S., et al., "Lymphokine-Activated Killer Cell Purging of Leukemia Cells from Bone Marrow Prior to Syngeneic Transplantation", Transplantation, Vol. 46, 433-438, No. 3, September 1988.

Gambarcorti-Passerini, C., et al., "Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells", British Journal of Haematology, 1991, 78, pp. 197-205.

Robertson, M. J., et al., "Biology and Clinical Relevance of Human Natural Killer Cells", Blood, Vol. 76, No. 12, (December 15), 1990: pp. 2421-2438.

Ellis, T. M., et al., "Functional Heterogeneity of Leu 19<sup>bright</sup><sup>+</sup> and Leu 19<sup>dim</sup><sup>+</sup> Lymphokine-Activated Killer Cells", The Journal of Immunology, Vol. 142, April 15, 1989, No. 8, pp. 2949-2954.

Ades, E. W., "Lymphokine-Activated Killer Cell Lysis of Human Neuroblastoma Cells: A Model for Purging Tumor Cells from Bone Marrow", Clinical Immunology and Immunopathology, 46, pp. 150-156 (1988).

Tschiyama, J. et al., "Characterization of a Novel Human Natural Killer-Cell Line (ND-YS) Established from Natural Killer Cell Lymphoma/Leukemia Associated with Epstein-Barr Virus Infection", Blood, Vol. 92, No. 4, (August 15), 1988: pp. 1374-1383.

Ingo, G. H., et al., "Use of a SCID Mouse/Human Lymphoma Model to Evaluate Cytokine-induced Killer Cells with Potent Antitumor Cell Activity", J. Exp. Med., Vol. 174, July 1991, pp. 139-149.

Hercend, T., et al., "Phenotypic and functional heterogeneity of human cloned natural killer cell lines", Nature, Vol. 301, January 13, 1983, pp. 158-160.

Alderson, M. R., "Interleukin 7 Enhances Cytolytic T Lymphocyte Generation and Induces Lymphokine-activated Killer Cells from Human Peripheral Blood", J. Exp. Med., Vol. 172, August 1990, pp. 577-787.

Robertson, M. J., et al., "Response of Human Natural Killer (NK) Cells to NK Cell Stimulatory Factor (NKSF): Cytolytic Activity and Proliferation of NK Cells are Differentially Regulated by NKSF", J. Exp. Med., March 1992, pp. 779-788.

Phillips, J. H., et al., "Dissection of the Lymphokine-Activated Killer Phenomenon", J. Exp. Med., Vol. 164, September 1986, pp. 814-825.

Rosenberg, S. A., et al., "Special Report - Observation on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer", The New England Journal of Medicine, Vol. 313, No. 23, Dec. 5, 1985, pp. 1485-1492.

Yodoi, J., et al., "TCGF (IL 2)-Receptor Inducing Factor(s)", Journal of Immunology, Vol. 134, No. 3, March 1985, pp. 1623-1630.

Mule, J. J., et al., "Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2", Science, Vol. 225, pp. 1487-1489.

Komiyama, A., et al., "Childhood Lymphoblastic Leukemia with Natural Killer Activity: Establishment of the Leukemia Cell Lines Retaining the Activity", Blood, Vol. 60, No. 6 (December), 1992, pp. 1429-1436.

Fernandez, L. A., et al., "Aggressive Natural Killer Cell Leukemia in an Adult With Establishment of an NK Cell Line", Blood, Vol. 67, No. 4 (April), 1986: pp. 925-930.

Suzuki, N., et al., "Natural Killer Lines and Clones with Apparent Antigen Specificity", J. Exp. Med., Vol. 172, August 1990, pp. 457-462.

Chin, Keh-Chuang, et al., "Activation and Transdominant Suppression of MHC Class II and HLA-DMB Promoters by a Series of C-Terminal Class II Transactivator Deletion Mutants", The Journal of Immunology, 0022-1767, 1997, pp. 2790-2794.

Schouten, Govert J., et al., "Downregulation of MHC Class I expression due to interference with p105-NFkB1 processing by Ad12E1A", The EMBO Journal, Vol. 14, No. 7, pp. 1498-1507, 1995.

Submitted herewith is Form PTO-1449 listing the above-identified references. Copies of the listed patents and publications are not provided herewith pursuant to 37 C.F.R. §1.98(d) since they were previously cited by or submitted to the Patent and Trademark Office during the prosecution of the above-identified co-pending applications.

Appln No. 10/008,955  
Filed December 7, 2001

**PATENT  
APPLICATION**


Pursuant to 37 CFR §1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b).

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Dated: February 12, 2002

By

  
\_\_\_\_\_  
Richard A. Kaba  
Reg. No. 30,562

120 South LaSalle Street  
Suite 1600  
Chicago, Illinois 60603-3406  
(312) 577-7000

FEB 27 2002  
PATENT & TRADEMARK OFFICE

Form PTO-1449

**Application Number**  
**10/008,955**

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant  
Hans KLINGEMANN

Filing Date  
December 7, 2001

### Group Art Unit

## U. S. PATENT DOCUMENTS

RECEIVED  
MAR - 4 2002  
ECHO CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

CLASS	SUB CLASS	Translation	
		Yes	No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

- |   |   |
|---|---|
| ✓ | Gong Jiang-Hong, et al., "Characterization of a Human Cell Line (NK-92) with Phenotypical and Functional Characteristics of Activated Natural Killer Cells", <i>LEUKEMIA</i> , Vol. 8, No. 4 (April), 1994: pp. 652-658                             |
| ✓ | Klingemann, Hans-Georg, et al., "A cytotoxic ND-cell line (NK-92) for ex vivo purging of leukemia from blood", <i>Biology of Blood and Marrow Transplantation</i> , 2:68-75 (1996)  |
| ✓ | Wong, E., et al., "Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12, <i>Bone Marrow Transplantation</i> , (1996) 18, pp. 63-71  |
| ✓ | Long, G. S., et al., "Lymphokine-Activated Killer Cell Purging of Leukemia Cells from Bone Marrow Prior to Syngeneic Transplantation", <i>Transplantation</i> , Vol. 46, 433-438, No. 3, September 1988   |
| ✓ | Gambarcorti-Passerini, C., et al., "Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells", <i>British Journal of Haematology</i> , 1991, 78, pp. 197-205. |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant

**COPY OF PAPER  
ORIGINALLY FILED**



Form PTO-1449

Application Number  
10/008.955

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

Applicant  
**Hans KLINGEMANN**

Filing Date  
December 7, 2001

### Group Art Unit

(Use several sheets if necessary)

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

- |   |  |
|---|--|
| ✓ | Hercend, T., et al., "Phenotypic and functional heterogeity of human cloned natural killer cell lines", <u>Nature</u> , Vol. 301, January 13, 1983, pp. 158-160  |
| ✓ | Alderson, M. R., "Interleukin 7 Enhances Cytolytic T Lymphocyte Generation and Induces Lymphokine-activated Killer Cells from Human Peripheral Blood", <u>J. Exp. Med.</u> , Vol. 172, August 1990, pp. 577-787  |
| ✓ | Robertson, M. J., et al., "Response of Human Natural Killer (NK) Cells to NK Cell Stimulatory Factor (NKSF): Cytolytic Activity and Proliferation of NK Cells are Differentially Regulated by NKSF", <u>J. Exp. Med.</u> , March 1992, pp. 779-788   |
| ✓ | Phillips, J. H., et al., "Dissection of the Lymphokine-Activated Killer Phenomenon", <u>J. Exp. Med.</u> , Vol. 164, September 1986, pp. 814-825   |
| ✓ | Rosenberg, S. A., et al., "Special Report - Observation on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer", <u>The New England Journal of Medicine</u> , Vol. 313, No. 23, Dec. 5, 1985, pp. 1485-1492 |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant



EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant

(Use several sheets if necessary)

**Application Number**  
**10/008,955**

**Filing Date**  
**December 7, 2001**

### Group Art Unit

EXAMINER  
INITIAL

DOCUMENT NUMBER

DATE \_\_\_\_\_

NAME \_\_\_\_\_

## CLASS

SUB  
CLASSFILING  
DATE IF  
APPROP.

RECEIVED

MAR - 4 2002

~~TECH CENTER 1600/2900~~

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER

DATE \_\_\_\_\_

COUNTRY

## CLASS

**SUB  
CLASS**

### Translation

**Yes**

No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

Chin, Keh-Chuang, et al., "Activation and Transdominant Suppression of MHC Class II and HLA-DMB Promoters by a Series of C-Terminal Class II Transactivator Deletion Mutants", *The Journal of Immunology*, 0022-1767, 1997, pp. 2790-2794

Schouten, Govert J., et al., "Downregulation of MHC Class I expression due to interference with p105-NFkB1 processing by Ad12E1A" The EMBO Journal. Vol. 14. No. 7, pp. 1498-1507. 1995

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant